European Society of Gene and Cell Therapy
The European Society of Gene and Cell Therapy (ESGCT) is a non-profit organisation for educational and scientific purposes. The aim of ESGCT is to promote fundamental and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
History
ESGCT was founded in January 1992 as the European Working Group on Human Gene Transfer and Therapy (EWGT).[1] The Society was renamed the European Society of Gene Therapy (ESGT) in 1998.[2] In 2007, the Society's name was changed again to ESGCT to better reflect that the fields of gene and cell therapy can not be readily separated from one another. In 2017 ESGCT celebrated its 25th anniversary at the Annual Congress in Berlin.[3][4]
Board and Presidents
The Board of ESGCT consists of 10 eminent scientists working in the fields of gene and/or cell therapy. Furthermore, one or two graduate students may be co-opted, non-voting, members of the Board. The presidency of ESGCT normally runs for 2 years. Presidents are elected at the Annual General Meeting that takes place at the Annual Congress. The following people have been elected President of the Society[1][5][6][7][8]
- 1992 - 1996 Claudio Bordignon
- 1996 - 1998 Olivier Danos
- 1998 - 2004 Bernd Gänsbacher
- 2004 - 2006 David Klatzmann
- 2006 - 2008 George Dickson
- 2008 - 2010 Thierry VandenDriessche
- 2010 - 2012 Seppo Ylä-Herttuala
- 2012 - 2014 Luigi Naldini
- 2014 - 2016 Nathalie Cartier
- 2016 - 2018 Robin Ali
- 2018- present Hildegard Büning
Congresses
The Annual Congress of the ESGCT take place in a different location in Europe every year to reflect the international character of the society. Since the first congress in 1993, Congresses have taken place in
- 1993: Baveno
- 1994: London
- 1995: Barcelona
- 1996: Leiden
- 1997: Milan
- 1998: Jerusalem
- 1999: Munich
- 2000: Stockholm
- 2001: Antalya
- 2002: Antibes
- 2003: Edinburgh
- 2004: Tempere
- 2005: Prague
- 2006: Athens
- 2007: Rotterdam
- 2008: Bruges
- 2009: Hannover
- 2010: Milan
- 2011: Brighton, joint with BSGT, now BSGCT
- 2012: Versailles, joint with SFTCG
- 2013: Madrid, joint with SETGyC
- 2014: The Hague, joint with NVGCT
- 2015: Helsinki, joint with FSGT
- 2016: Florence, joint with the International Society for Stem Cell Research
- 2017: Berlin, joint with DG-GT
- 2018: Lausanne, joint with SFTCG and the International Society for Stem Cel Research
- 2019: Barcelona, joint with SETGyC
References
- ^ a b Cohen-Haguenauer, Odile (2013-01-01). "A Historical View on the Creation of the European Society for Cell and Gene Therapy". Human Gene Therapy. 24 (1): 4–11. doi:10.1089/hum.2012.2524. ISSN 1043-0342. PMID 23339284.
- ^ Axelrod, Jonathon H. (1999-01-01). "Sixth meeting of the European Working Group on Human Gene Transfer and Therapy (EWGT) Jerusalem, Israel, November 21–24, 1998". The Journal of Gene Medicine. 1 (1): 74–76. doi:10.1002/(sici)1521-2254(199901/02)1:1<74::aid-jgm9>3.0.co;2-z. ISSN 1521-2254.
- ^ "European Society for Gene and Cell Therapy". www.facebook.com. Retrieved 2017-06-21.
- ^ "Current Congress Information". www.esgct.eu. Retrieved 2017-06-21.
- ^ Müller, Stefan; Simon, Jürgen W.; Vesting, Jan W. (2012-12-06). Interdisciplinary Approaches to Gene Therapy: Legal, Ethical and Scientific Aspects. Springer Science & Business Media. ISBN 9783642608292.
- ^ "EC Grant Part C". www.weizmann.ac.il (in Hebrew). Retrieved 2017-06-21.
- ^ Cohen-Haguenauer, Odile (2013-05-03). The Clinibook: Clinical gene transfer state of the art. EDK Editions. ISBN 9782842542375.
- ^ "Board Members". www.esgct.eu. Retrieved 2017-06-21.
